Depression is a mental health disorder characterized by persistent depressed mood or loss of interest or pleasure, accompanied by changes in thinking, behavior, and physical functioning. It differs from ordinary sadness through its duration, associated symptoms, and effects on everyday life. In a depressive episode, symptoms generally occur for most of the day, nearly every day, for at least two weeks. The term commonly refers to major depressive disorder, although clinical classifications distinguish several depressive disorders and patterns of presentation. (who.int)
Depression is important to public health because it is common, can impair relationships and participation in education and employment, and is associated with disability and suicide. Its development involves interacting biological, psychological, and social factors rather than a single established cause. Diagnosis depends on clinical assessment, while treatment can include psychological therapies, medication, and, in selected circumstances, brain stimulation. This article examines its classification, manifestations, distribution, contributing factors, assessment, treatment, long-term course, and research history. (who.int)
Terminology and Clinical Classification
Depression can denote a mood symptom, an episode, or a classified mental disorder. Depressed mood is an emotional state and, by itself, does not establish a psychiatric diagnosis; temporary sadness following disappointment or loss is not necessarily a depressive disorder. A depressive episode is a sustained combination of mood, cognitive, and bodily symptoms that meets specified clinical requirements. A depressive disorder describes the broader diagnostic condition, incorporating the episode pattern, duration, functional consequences, and relevant exclusions. These levels are not equivalent: depressive episodes also occur in bipolar disorders, where they are classified within the bipolar illness rather than as a separate unipolar depressive disorder. (psychiatry.org)
The two principal classification frameworks are the World Health Organization’s International Classification of Diseases, eleventh revision (ICD-11), and the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, fifth edition, text revision (DSM-5-TR). ICD-11 was adopted by the World Health Assembly in May 2019 and took effect as a basis for health reporting in January 2022; WHO published its accompanying Clinical Descriptions and Diagnostic Requirements in March 2024. DSM-5-TR was published in 2022. ICD provides an international classification and reporting framework, whereas DSM supplies psychiatric diagnostic criteria and descriptive text. DSM-5-TR uses ICD-10-CM codes for United States reporting; this coding relationship does not make its diagnostic categories identical to those of ICD-11. (who.int)
In DSM terminology, major depressive disorder (MDD) requires at least one major depressive episode together with the applicable exclusions, including the absence of a history of manic or hypomanic episodes. The episode threshold is five or more of nine specified symptoms during the same two-week period, representing a change from previous functioning; at least one must be depressed mood or markedly diminished interest or pleasure. Clinically significant distress or functional impairment is also required. “Major” identifies the diagnostic syndrome, not an assertion that every episode is severe: MDD can have mild, moderate, or severe presentations and can be described as single-episode or recurrent. ICD-11’s depressive episode threshold similarly requires at least five symptoms, but from a list of ten: hopelessness about the future is a separate counted symptom, whereas DSM includes hopelessness as an example of depressed mood. (psychiatry.org)
ICD-11 separates single episode depressive disorder (6A70) from recurrent depressive disorder (6A71). The former applies to a first or only depressive episode; the latter requires at least two episodes separated by several months without significant mood disturbance. Neither category permits a history of manic, mixed, or hypomanic episodes. Thus, DSM’s single-episode and recurrent forms of MDD broadly correspond to two separate ICD-11 disorder categories, but correspondence is not exact equivalence. Both systems additionally describe episode severity, psychotic symptoms, and remission status; these descriptors refine the classification rather than replacing the underlying disorder category. (iris.who.int)
Chronic depressive presentations illustrate a further difference. DSM-5-TR’s persistent depressive disorder requires depressed mood for most of the day, on more days than not, for at least two years in adults, or one year in children and adolescents, with accompanying symptoms. It encompasses presentations formerly classified as dysthymic disorder as well as chronic major depression. ICD-11 retains dysthymic disorder (6A72), requiring persistent depressive mood for at least two years but excluding a full depressive episode during the first two years. A continuously syndromal depressive episode lasting two years is therefore not automatically ICD-11 dysthymia. DSM-5-TR removed the parenthetical label “dysthymia” from persistent depressive disorder because the older term suggested a narrower condition that excluded major depressive episodes during the initial two years. Consequently, “persistent depressive disorder” and “dysthymia” should not be treated as interchangeable labels across manuals or editions. (psychiatry.org)
Symptoms and Functional Impairment
Depressed mood may be experienced as persistent sadness, emptiness, or irritability rather than as continuous tearfulness. A second central symptom is anhedonia, a marked reduction in interest or pleasure: previously enjoyable activities, such as listening to music, meeting friends, or pursuing a hobby, may lose their appeal. These symptoms distinguish depressive episodes from ordinary, short-lived mood fluctuations; during an episode, depressed mood or diminished interest typically occurs for most of the day, nearly every day, for at least two weeks. Not everyone experiences the same combination of symptoms, and an absence of obvious sadness does not exclude a presentation dominated by loss of interest or pleasure. (who.int)
Changes in thinking include hopelessness about the future, excessive guilt, and feelings of worthlessness. Hopelessness concerns expectations that circumstances will not improve, whereas worthlessness concerns a negative judgment of oneself; guilt may involve disproportionate self-blame. Concentration, memory, and decision-making can also be impaired. Their practical manifestations include difficulty following a conversation, retaining what has been read, or deciding how to begin an everyday task. These cognitive symptoms can accompany low mood, but may themselves be prominent reasons for difficulty at school or work. Thoughts of death or suicide are possible additional symptoms, although they are not present in everyone with depression. (who.int)
Sleep, appetite, energy, and movement may change in different directions. Sleep disturbance can involve difficulty falling asleep, waking during the night or unusually early, or sleeping excessively. Appetite may decrease or increase, sometimes with unintended weight loss or gain. Fatigue and diminished energy can make routine activities unusually demanding. Psychomotor disturbance refers to changes in movement and activity: slowing may affect bodily movements and speech, while agitation may appear as observable restlessness or difficulty remaining still. Slowing is therefore not simply another name for tiredness, and agitation can occur despite low mood and reduced energy. (nimh.nih.gov)
Functional impairment extends beyond the subjective experience of distress. Personal care and household routines may become difficult to maintain; withdrawal and reduced engagement may affect relationships with family and friends. In educational settings, reduced attention and energy can interfere with studying and completing assignments. At work, similar difficulties can disrupt task completion and the ability to meet responsibilities. These examples illustrate how emotional, cognitive, and physical symptoms translate into limitations in daily activities, rather than forming a separate symptom category. The extent of these limitations varies between individuals and is considered alongside symptoms when evaluating severity. (iris.who.int)
Some presentations are dominated by physical complaints, including headaches, diffuse aches, cramps, gastrointestinal discomfort, or persistent fatigue, rather than an explicit report of sadness. Such complaints can be the main reason for seeking medical care. Depression can also coexist with chronic physical illness or pain, so a physical complaint is not evidence by itself that its origin is psychological. Symptoms overlap with those of medical conditions and medication effects; distinguishing these possibilities belongs to clinical assessment, rather than to the symptom list alone. (who.int)
Severity and Patterns of Presentation
Severity assessment combines the number and intensity of symptoms with their effects on daily functioning; episode duration and the course of illness provide additional context. In the ICD-11, depressive episodes are described as mild, moderate, or severe. Mild episodes cause distress and some difficulty maintaining activities; severe episodes markedly restrict functioning across personal, family, social, educational, or occupational settings. These dimensions do not always coincide: continued employment, for example, does not establish that symptoms are mild. NICE’s 2022 guideline emphasizes assessment of symptom severity, duration, previous history, and functional impairment rather than a symptom count alone. A prolonged episode may accumulate substantial impairment without necessarily meeting the criteria for severe current symptoms; chronicity and current severity therefore describe different aspects of the presentation. (nice.org.uk)
Psychotic presentations involve delusions or hallucinations during a depressive episode, rather than simply intense pessimism or self-criticism. Their content may be mood-congruent, reflecting depressive themes such as guilt, deserved punishment, personal inadequacy, or disease, or mood-incongruent, without that thematic relationship. A delusional conviction of having committed an unforgivable offence illustrates the former. Psychotic symptoms and overall depressive severity are recorded separately: the World Health Organization’s 2024 ICD-11 clinical manual includes both moderate and severe depressive episodes with psychotic symptoms. The DSM-5-TR, published in 2022, likewise permits specification of mood-congruent or mood-incongruent psychotic features. (psychiatry.org)
Melancholic presentations emphasize pervasive loss of pleasure and limited emotional responsiveness to normally pleasurable experiences. Associated features include early-morning awakening, worse symptoms in the morning, marked slowing or agitation, and reduced appetite or weight. DSM melancholic criteria require either near-complete loss of pleasure or lack of mood reactivity, together with at least three additional features; these include excessive or inappropriate guilt and a distinctively profound quality of depressed mood. ICD-11 provides the additional qualifier “current depressive episode with melancholia,” but its requirements are not identical to the DSM formulation. These labels characterize an episode rather than establishing an independent depressive disorder. (pmc.ncbi.nlm.nih.gov)
The DSM “with atypical features” specifier describes a different pattern: mood can brighten in response to positive events, accompanied by at least two of increased appetite or weight, excessive sleep, heavy or “leaden” feelings in the limbs, and longstanding sensitivity to interpersonal rejection that impairs functioning. Temporary mood improvement does not exclude an otherwise qualifying depressive episode. ICD-11 does not provide a directly corresponding named atypical qualifier among its additional mood-episode codes. Anxiety can also be prominent without meeting the requirements for a separate anxiety disorder. DSM uses “with anxious distress,” while ICD-11 uses “with prominent anxiety symptoms” and additionally allows panic attacks to be recorded; the labels and thresholds should not be treated as interchangeable. (pmc.ncbi.nlm.nih.gov)
A seasonal pattern concerns the repeated timing of episode onset and remission, not a distinctive level of severity. A common example is depression beginning in autumn or winter and improving in spring; summer episodes also occur. The seasonal designation describes a recurrent relationship with a particular season, rather than ordinary fluctuations in mood during darker months. DSM-5-TR identifies major depressive disorder with seasonal pattern, while ICD-11 supplies an additional seasonal-pattern qualifier. Seasonal timing can coexist with symptom patterns such as increased sleep and appetite. (psychiatry.org)
Pregnancy- and childbirth-related designations likewise describe timing rather than necessarily identifying a separate disorder. The DSM “with peripartum onset” specifier applies when an episode begins during pregnancy or within four weeks after delivery. ICD-11’s associated additional coding covers onset during pregnancy or within six weeks after delivery. These formal windows are narrower than the broader clinical and public-health use of perinatal depression, which commonly includes depression during pregnancy and the first postpartum year. An episode beginning several months after childbirth may therefore be described clinically as postpartum depression without meeting the DSM peripartum-onset timing requirement. (pmc.ncbi.nlm.nih.gov)
Epidemiology and Population Burden
The World Health Organization (WHO), in its fact sheet updated on 11 September 2026, estimated that 5.2% of adults experienced depression in 2023. The corresponding estimate for the entire population, including children, was 4%, or approximately 322 million people. Adult prevalence was estimated at 4.1% among men and 6.2% among women—about a 1.5-fold difference—and at 5.4% among people aged 70 years or older. These figures refer to a specified estimation year, not to lifetime experience or the proportion of people receiving treatment. WHO separately estimated that 43 million children and adolescents were living with depression in 2023. (who.int)
In epidemiology, prevalence measures existing cases within a defined population and time frame. Point prevalence concerns cases present at a particular time; annual prevalence, a form of period prevalence, includes people meeting the case definition at any time during a year. Lifetime prevalence concerns people who have met that definition at any point before assessment, including those whose symptoms have resolved. It is therefore not the same as the probability of developing depression over a complete lifespan. Incidence, by contrast, concerns new cases. Prevalence reflects both the occurrence of new illness and how long illness persists, so populations with similar incidence can have different prevalence when episode duration differs. (archive.cdc.gov)
Age patterns depend on the population, period, and outcome measured. The United States’ 2021 National Survey on Drug Use and Health estimated that 8.3% of adults had experienced a major depressive episode during the preceding year: 18.6% among those aged 18–25, 9.3% at ages 26–49, and 4.5% at ages 50 or older. The estimates were 10.3% among women and 6.2% among men. These national, past-year episode estimates are not directly interchangeable with WHO’s global depression estimates. Moreover, observed differences do not themselves establish their causes. A 2011 cross-national analysis by Evelyn Bromet and colleagues found that associations between age and depression varied across countries; its discussion distinguished possible cohort effects from differences in the recall of previous episodes. Such findings do not support a single universal age gradient or a causal explanation based on prevalence comparisons alone. (nimh.nih.gov)
Survey methods and case definitions materially affect estimates. Bromet and colleagues analysed interviews with 89,037 adults in 18 countries, using a common structured diagnostic instrument. Average lifetime prevalence of DSM-IV major depressive episodes was 14.6% in the participating high-income countries and 11.1% in the low- and middle-income countries; the authors identified differential recall as a possible contributor to cross-national differences. Sampling coverage, response rates, translation, and the interpretation of diagnostic questions also affect comparability. An episode definition is not necessarily equivalent to a depressive-disorder diagnosis: for example, the 2021 US survey did not exclude depressive symptoms attributed to medical illness, substance use disorders, or medication. A symptom questionnaire’s threshold likewise should not be treated as automatically equivalent to a structured diagnostic assessment. (pmc.ncbi.nlm.nih.gov)
Population burden includes the severity and duration of disability, not simply the number of affected people. The Global Burden of Disease 2021 study estimated that depressive disorders—major depressive disorder and dysthymia combined—accounted for 56.3 million years lived with disability, with a 95% uncertainty interval of 39.3–76.5 million. Years lived with disability weight time spent in different health states by the magnitude of health loss; the weights range from 0 for full health to 1 for a state equivalent to death. Disability-adjusted life years additionally include years lost to premature mortality. In this study, depressive disorders’ directly assigned burden was entirely nonfatal, so their disability-adjusted total also equalled 56.3 million years, or 1.9% of all-cause disability-adjusted life years. That accounting convention does not imply that depression has no relationship with mortality. (healthdata.org)
Psychological and Social Contributors
Abuse, neglect, bereavement, traumatic experiences, and unemployment are associated with an increased likelihood of depression. Their effects occur within an interaction of social circumstances, psychological processes, and biological susceptibility, rather than through a single necessary or sufficient cause. The World Health Organization also describes a reciprocal process: adverse circumstances can contribute to depression, while depression can increase stress and impair functioning, worsening those circumstances. Thus, relationship breakdown or loss of employment may precede an episode, follow its onset, or do both. An association between an event and depression does not establish that the event caused a particular person’s illness. (who.int)
Childhood adversity can have associations extending into adulthood. In a 2007 prospective study, Cathy Spatz Widom and colleagues followed 676 children with documented abuse or neglect before age 11 and 520 matched comparison children into young adulthood. Documented maltreatment was associated with higher odds of current major depressive disorder at follow-up: an odds ratio of 1.51, with a 95% confidence interval of 1.06–2.14. Because the maltreatment records preceded the adult assessment, this design reduced reliance on adults retrospectively recalling childhood experiences. Nevertheless, matching cannot remove every difference between exposed and unexposed groups, and the finding represents elevated odds, not an inevitable outcome. Bereavement is another relevant exposure, but the occurrence of distress after a death does not by itself establish a depressive disorder. (pubmed.ncbi.nlm.nih.gov)
Poverty and insecure employment are important social determinants of health. A 2020 review by Matthew Ridley, Gautam Rao, Frank Schilbach, and Vikram Patel examined evidence for effects in both directions: adverse economic shocks can worsen depression and anxiety, while mental illness can reduce employment and income. Evidence from antipoverty interventions, including cash transfers, provides stronger grounds for causal interpretation than a simple comparison of richer and poorer people, although outcomes often concern combined depression-and-anxiety measures rather than diagnosed depressive disorder alone. Proposed pathways include financial uncertainty and exposure to adverse living conditions; in the opposite direction, impaired functioning can diminish economic opportunities. These processes can create feedback between material disadvantage and psychological distress. (pubmed.ncbi.nlm.nih.gov)
Social isolation and loneliness are related but distinct: isolation concerns limited social contact, whereas loneliness concerns the perceived inadequacy of relationships. In a study published in 2021, Siu Long Lee and colleagues analysed 4,211 adults aged 50 or older in England with complete data over 12 years. Greater baseline loneliness predicted higher subsequent depressive symptom scores even after adjustment for social isolation, social support, initial symptoms, and other measured factors. This establishes a longitudinal association, not proof that eliminating loneliness would prevent the corresponding cases. Relationship difficulties may likewise be both contributors to distress and consequences of depressive withdrawal or impaired functioning. (pubmed.ncbi.nlm.nih.gov)
Rumination—repetitive attention to distress and its possible causes and consequences—is studied as a possible maintaining process. In Susan Nolen-Hoeksema and Jannay Morrow’s 1993 experiment, participants were randomly assigned to eight minutes of ruminative or distracting attention. Among initially depressed participants, rumination worsened mood while distraction improved it; neither manipulation affected nondepressed participants’ mood. This supports a short-term effect on mood, not proof that rumination alone causes a clinical episode. Avoidance is another proposed process: disengagement from problems may leave stressors unresolved. Charles Holahan and colleagues’ 2005 study followed 1,211 late-middle-aged adults for ten years; baseline avoidance predicted more stressors four years later, which statistically linked avoidance with later depressive symptoms after accounting for initial symptoms. Such longitudinal models identify plausible pathways but remain vulnerable to confounding and reciprocal effects; they do not establish personal blame for persistent depression or interpersonal adversity. (tandfonline.com)
Biological Factors and Mechanistic Research
Genetic susceptibility to depression is distributed across many variants rather than determined by a single gene. A 2025 genome-wide association meta-analysis by the Psychiatric Genomics Consortium included 688,808 people classified as having major depression and 4,364,225 controls from 29 countries. It identified 697 independent associations across 635 genomic regions, implicating processes including neuronal differentiation and receptor organization. These are statistical associations: an associated region does not necessarily identify the causal variant or establish how it affects symptoms. Genetic vulnerability operates alongside environmental experience, and inherited susceptibility is not equivalent to an inevitable depressive episode. Research therefore examines both accumulated genetic effects and the biological responses through which experience may influence vulnerability. (discovery.ucl.ac.uk)
Environmental experience can affect biological function without changing the DNA sequence. One research question concerns changes in gene activity over the life course; another concerns how stress alters communication between neurons. Experimental work provides specific examples but requires careful interpretation. In a mouse study reported in 2019, Conor Liston and colleagues found that sustained stress exposure increased the elimination and reduced the formation of dendritic spines in the prefrontal cortex. These small protrusions receive many of a neuron’s synaptic inputs. Stress also reduced coordinated activity among prefrontal neurons. Such findings offer experimentally testable mechanisms connecting exposure to circuit function, but depression-related behaviors in mice do not reproduce the full human disorder. (nimh.nih.gov)
Research on human brain circuits examines systems involved in emotional processing, reward, and cognitive control rather than locating depression in one isolated brain region. Studies using functional magnetic resonance imaging and other imaging methods have associated altered reward responses with anhedonia, including differences in circuits influenced by dopamine. Circuit function can also be investigated by perturbing activity: a study reported by NIMH in 2024 examined 36 unmedicated adults with depression, mapping connections between the prefrontal cortex and subgenual anterior cingulate cortex before targeted stimulation. The initial response in the deeper region predicted subsequent symptom improvement. Such results identify candidate pathways involved in treatment response; they do not establish that the same circuit abnormality causes every depressive episode. (nimh.nih.gov)
Neurotransmitter research includes serotonin, noradrenaline, dopamine, and glutamate, but a drug’s molecular target must be distinguished from an established explanation of the disorder. Selective serotonin reuptake inhibitors block the transporter that normally returns released serotonin to the presynaptic neuron, thereby modifying serotonergic signaling. Conventional monoaminergic antidepressants commonly require several weeks for their fuller clinical effects, unlike their initial molecular action. Their effectiveness shows that changing these systems can relieve symptoms in some people; it does not demonstrate that depression was caused by a pre-existing serotonin deficiency. A simple “chemical imbalance” is therefore not established as the general cause of depression, whose biological investigation encompasses genetic, environmental, and circuit-level processes. (nimh.nih.gov)
Ketamine research provides a contrasting route into synaptic plasticity, the capacity of neural connections to change. Ketamine blocks the glutamate-sensitive NMDA receptor. In 2000, a Yale team including John Krystal and Dennis Charney reported rapid antidepressant effects in a small randomized trial; Carlos Zarate and colleagues extended this work in 2006 among people with treatment-resistant depression. Effects appearing within hours prompted investigation of mechanisms beyond conventional monoamine reuptake inhibition. In Liston’s 2019 mouse study, ketamine restored coordinated prefrontal activity and altered behavior within about three hours, whereas new dendritic spines appeared over approximately 12–24 hours. Selectively removing newly formed spines disrupted the sustained improvement in certain behaviors. This separated processes associated with the initial response from those maintaining it, while leaving open how completely the mouse mechanism explains antidepressant effects in humans. (nimh.nih.gov)
Clinical Assessment and Diagnosis
Clinical diagnosis establishes whether depressive symptoms form a sustained episode, how they affect daily functioning, and whether another condition better explains them. The interview documents depressed mood or loss of interest, associated cognitive and physical symptoms, their onset and persistence, and changes from the person’s usual functioning. Assessment includes effects on work, study, relationships, and self-care rather than assuming that outward activity excludes illness. Previous depressive episodes, periods of improvement, and responses to earlier treatment help establish the course of the condition. The UK National Institute for Health and Care Excellence’s 2022 guideline explicitly distinguishes comprehensive assessment from simply counting symptoms. (nice.org.uk)
Diagnostic thresholds depend on the classification system used. In DSM-5, a major depressive episode requires at least five of nine specified symptoms during the same two-week period, including depressed mood or loss of interest or pleasure. The symptoms must cause clinically significant distress or impairment, and the episode must not be attributable to a substance or another medical condition. Duration alone therefore does not establish a diagnosis. The World Health Organization published its clinical diagnostic manual for ICD-11 on March 8, 2024; its requirements are applied within that classification rather than treated as interchangeable with DSM terminology. (nice.org.uk)
Investigation of previous manic or hypomanic episodes is essential because a depressive episode can occur within bipolar disorder. Clinicians ask about distinct periods of unusually elevated or irritable mood, increased activity, reduced need for sleep, and disinhibited behavior, including their duration and consequences. NICE’s bipolar guideline specifies asking adults presenting with depression about previous overactivity or disinhibition; its four-day threshold prompts consideration of specialist assessment, not an automatic diagnosis. A specialist history also examines changes between episodes, family history, triggers, and corroborating information from relatives or carers. (nice.org.uk)
The medical assessment reviews physical illnesses, prescribed medicines, alcohol, and other substances. Physical examination and laboratory investigations can identify alternative or contributing explanations: thyroid disorders and anemia, for example, may produce symptoms that overlap with depression. There is no laboratory test that independently diagnoses a depressive disorder; blood tests investigate possible medical contributors rather than confirm depression. Psychosocial assessment records bereavement, trauma, relationship difficulties, housing and employment circumstances, debt, isolation, and available support. Questions about suicidal thoughts and intent form part of the clinical assessment, although detailed risk evaluation is a separate component. (nimh.nih.gov)
Interviews provide the context in which standardized symptom measures are interpreted. Self-report questionnaires and clinician-rated measures can quantify symptom severity and support evaluation over time, but a score does not establish the episode’s cause or replace diagnostic assessment. Clinicians also review mental state and functional difficulties, using interpreters or other communication adaptations when needed; family or carer observations can supplement the person’s account. Thus, a questionnaire indicating substantial symptoms still requires examination of duration, impairment, episode history, and competing explanations before a diagnosis is assigned. (nice.org.uk)
Screening and Symptom Measurement
Population screening systematically tests people who have not presented with recognized depressive symptoms; clinical case identification investigates possible depression when symptoms, history, or circumstances raise concern. Neither establishes a diagnosis by itself. In its June 2023 recommendation, the US Preventive Services Task Force supported adult depression screening, including during pregnancy and postpartum, with positive results followed by diagnostic evaluation and access to appropriate care. By contrast, NICE’s 2022 adult guideline describes targeted identification, particularly in people with previous depression or chronic physical illness accompanied by functional impairment. Diagnostic confirmation incorporates symptom duration, impairment, clinical history, and alternative explanations rather than treating a questionnaire threshold as sufficient. (uspreventiveservicestaskforce.org)
The Patient Health Questionnaire provides two related self-report instruments. The PHQ-2 asks about the frequency of depressed mood and loss of interest or pleasure during the preceding two weeks; its two items are each scored from 0 to 3, giving a total of 0–6. Kurt Kroenke, Robert L. Spitzer, and Janet B. W. Williams validated it in 2003 using data from 6,000 primary-care and obstetrics–gynecology patients, with independent mental-health-professional interviews in 580. A threshold of at least 3 had 83% sensitivity and 92% specificity in that interview sample. Its brevity makes it suitable for initial identification, but a positive result requires fuller assessment. The PHQ-9 assesses nine symptom domains over the same two-week period, producing a total of 0–27. The authors’ 2001 validation established commonly used symptom-severity bands beginning at scores of 5, 10, 15, and 20; these bands describe reported symptom burden, not independently confirmed clinical categories. (pubmed.ncbi.nlm.nih.gov)
Screening accuracy depends on the threshold, population, and diagnostic reference standard. A 2021 individual-participant-data meta-analysis included 44,503 participants from 100 studies. Against semistructured diagnostic interviews, a PHQ-9 threshold of at least 10 yielded pooled sensitivity and specificity of approximately 85% each: some interview-confirmed cases were missed, while some people without interview-confirmed major depression screened positive. The proportion of positive results that represent confirmed cases also depends on prevalence. As a hypothetical illustration, applying these estimates to 1,000 people with 10% prevalence would produce approximately 85 true-positive and 135 false-positive results; only about 39% of positive screens would represent confirmed cases. This calculation illustrates why a positive screen is not a diagnosis, rather than predicting outcomes in every setting. (bmj.com)
Clinician-administered instruments principally quantify symptom severity and treatment-related change. Max Hamilton published the Hamilton Depression Rating Scale in 1960; a commonly used version scores 17 items. Stuart A. Montgomery and Marie Åsberg introduced the ten-item Montgomery–Åsberg Depression Rating Scale in 1979, selecting items for their sensitivity to change during antidepressant treatment. These measures convert interview findings and observations into standardized ratings. Their scores depend on the symptoms included, scoring conventions, and consistency between raters; they are not interchangeable with one another or with self-report scores, and they do not replace diagnostic assessment. (pmc.ncbi.nlm.nih.gov)
Translation alone does not establish equivalent measurement across languages or populations. Validation examines whether items retain their meaning, whether scores relate appropriately to clinical findings, and whether people with comparable symptom levels respond similarly across groups. A 2012 study of 739 English-speaking and 221 French-speaking Canadian patients with systemic sclerosis found differential item functioning in three PHQ-9 items, but the differences did not materially alter overall symptom estimates. Its findings concerned that particular population, rather than all English and French speakers. (pmc.ncbi.nlm.nih.gov)
Repeated scores serve a different purpose from initial screening: they document symptom trajectories during care. NICE’s 2022 guideline supports routine outcome monitoring with validated measures such as the PHQ-9 and treatment review two to four weeks after initiation. Interpretation includes the changing pattern of individual symptoms, functioning, adverse effects, and clinical circumstances—not merely whether the total crosses a cutoff. Symptom reduction and restoration of quality of life are related but distinct outcomes; NICE accordingly includes measures of functioning and disability alongside symptom assessment. (nice.org.uk)
Differential Diagnosis and Coexisting Conditions
A depressive episode may occur within bipolar disorder, rather than a depressive disorder without manic or hypomanic episodes. The distinction depends on the longitudinal history, not simply the appearance of the current depression. Clinicians investigate previous periods of unusually elevated or irritable mood accompanied by increased energy or activity, reduced need for sleep, rapid speech, racing thoughts, or uncharacteristic risk-taking. Hypomania may not have been perceived as an illness because it caused less disruption than mania. Bipolar I disorder is distinguished by a history of mania; bipolar II disorder involves hypomanic and depressive episodes without a manic episode. Ordinary fluctuations in mood or an isolated period of irritability do not establish either diagnosis. (nimh.nih.gov)
An identifiable stressor does not by itself distinguish depression from adjustment disorder. The World Health Organization’s 2024 clinical requirements for the ICD-11 describe adjustment disorder through preoccupation with a stressor or its consequences and difficulty adapting, with resulting impairment. Depressive symptoms may occur, but a presentation meeting the requirements for a depressive episode is classified accordingly rather than as adjustment disorder. Bereavement likewise does not automatically exclude depression. In ordinary grief, painful feelings commonly fluctuate and remain connected to memories of the deceased; depressive episodes more often involve pervasive loss of pleasure and generalized worthlessness. Grief and depression can coexist. (drugsandalcohol.ie)
Prolonged grief disorder is distinguished by persistent yearning for, or preoccupation with, the deceased, accompanied by emotional pain and functional impairment beyond culturally expected grieving. Its time requirements differ between classification systems: ICD-11 requires persistence for at least six months after the loss, whereas DSM-5-TR specifies at least 12 months for adults and six months for children and adolescents. Duration alone is insufficient; the pattern, severity, impairment, and cultural context also matter. Unlike the broader negative mood and diminished interest of a depressive episode, prolonged grief remains centrally organized around the interpersonal loss. Both diagnoses may be present when their respective requirements are met. (drugsandalcohol.ie)
Substances, medications, and physical illness can produce depressive symptoms or coexist with an independent depressive disorder. Assessment reconstructs the timing of symptoms relative to intoxication, withdrawal, medication exposure, and the onset or progression of illness. Alcohol-related states and stimulant withdrawal, for example, can involve depressed mood; persistence outside substance-related periods helps clarify whether an independent disorder is also present. Thyroid disorders and some infections can produce symptoms resembling depression, while medicines used for other illnesses may contribute to mood changes. Physical examination and clinically indicated laboratory investigations address suspected causes; there is no single laboratory test that confirms a depressive disorder. Establishing a medical cause requires more than observing that low mood and physical disease occur together. (ncbi.nlm.nih.gov)
Coexisting psychiatric conditions include anxiety disorders, substance use disorders, eating disorders, and attention-deficit/hyperactivity disorder. Shared features—such as poor concentration, disrupted sleep, and withdrawal—do not alone establish multiple diagnoses. ICD-11, for example, permits an additional generalized anxiety disorder diagnosis when its requirements were met before the depressive episode or following its complete remission. Post-traumatic stress disorder differs through trauma-related re-experiencing in the present, avoidance, and a continuing sense of threat, although depressive episodes can coexist with it. The temporal course and disorder-specific features therefore matter alongside overlapping symptoms. (nimh.nih.gov)
The relationship with chronic physical illness is not limited to diagnostic mimicry. Depression can accompany diabetes, cancer, cardiovascular disease, and chronic pain; people with both conditions tend to experience more severe symptoms of each. Illness-related pain, disability, and restrictions on daily life can contribute to depression, while depression can interfere with physical activity, attendance at appointments, and adherence to medical treatment. Fatigue, appetite change, and sleep disturbance may reflect either condition or both, making attribution difficult. Clinical assessment considers affective and cognitive symptoms together with the physical disease’s course, rather than treating depression as an inevitable or merely understandable consequence of chronic illness. (nimh.nih.gov)
Suicide and Other Serious Complications
Thoughts of death, suicidal ideation, and suicide attempts are possible complications of depression, but they are not experienced by everyone with a depressive disorder. Suicidal thoughts and suicidal behavior are related but distinct: assessment differentiates thoughts about dying from intent to act and from previous actions. Depression is an important contributor to suicide, although suicidal behavior has multiple psychological, social, biological, and environmental determinants and cannot be attributed to a diagnosis alone. The World Health Organization estimated that 727,000 people died by suicide worldwide in 2021; this figure covers all suicides, not deaths attributable specifically to depression. Previous suicide attempts, alcohol use disorders, relationship crises, financial difficulties, chronic pain, and isolation are among the circumstances associated with suicidal behavior. (who.int)
Professional assessment involves a direct clinical conversation rather than inference from the apparent severity of depressed mood. The US National Institute of Mental Health’s adult assessment guide addresses the frequency and recency of suicidal thoughts, current intent, the presence of a plan and access to means, and previous self-injury or attempts, including their timing and intent. It also examines hopelessness, agitation, impulsivity, substance use, and current circumstances such as domestic conflict or work-related stress. Protective factors include supportive relationships and personally meaningful reasons for living, such as family commitments or beliefs. These are considered alongside vulnerabilities rather than treated as guarantees of safety. Relevant information from relatives, carers, and existing records can help establish context, with attention to consent and confidentiality. (nimh.nih.gov)
Assessment is directed toward identifying needs and deciding how immediate and continuing safety can be supported; it does not reliably predict an individual’s future behavior. England’s National Institute for Health and Care Excellence (NICE), in its 2022 guideline on self-harm, explicitly advises against using risk scales or global “low,” “medium,” or “high” categories to predict suicide, determine access to treatment, or decide discharge. Instead, a psychosocial assessment considers historical, current, anticipated, and protective factors together. Clinician-developed safety plans can document individualized coping responses, supportive contacts, service arrangements, and collaborative measures to reduce access to lethal means. They differ from a promise not to act on suicidal thoughts, which the NIMH guide identifies as ineffective and potentially falsely reassuring. (nice.org.uk)
Severe depression can also compromise basic self-care independently of suicidal intent. NICE identifies self-neglect as a reason to consider crisis services or specialist care and specifically recognizes depression accompanied by failure to eat or drink as potentially life-threatening. This is more than an appetite symptom: inability to maintain adequate intake can make rapid treatment necessary. The same guideline lists a need for rapid response—for example, when a person is not eating or drinking—as one circumstance in which electroconvulsive therapy may be considered. Its procedure and adverse effects are addressed separately from the assessment of these complications. (nice.org.uk)
The care setting depends on whether psychiatric and physical needs can be managed safely outside hospital. NICE’s adult depression guideline describes crisis-resolution and home-treatment services for severe depression involving significant suicide risk, self-harm, self-neglect, or treatment-related complications, including those associated with medical comorbidity in older adults. Inpatient treatment is considered when adequate support cannot be provided through these services. Following an episode of self-harm, emergency and hospital care combine treatment of physical injury with specialist psychosocial assessment rather than treating either as a substitute for the other. (nice.org.uk)
Depression Across the Life Course
In children, depression may be expressed through irritability, anxiety, clinginess, physical complaints, or refusal to attend school rather than a clear description of sadness. Older children and adolescents may show frustration, restlessness, low self-esteem, or behavioral difficulties at school. These presentations can obscure the underlying mood disturbance, particularly when adults initially interpret them as disobedience or ordinary developmental changes. Adolescents may also withdraw from friends and family, lose interest in activities, and experience changes in sleep and appetite. Impaired concentration and fatigue can coincide with falling grades; withdrawal reduces participation in the peer relationships and activities through which social skills develop. Effects on schooling and relationships are therefore important aspects of impairment, not merely secondary consequences of reported mood symptoms. (nimh.nih.gov)
Perinatal depression encompasses depressive illness during pregnancy and after childbirth. Its presentation includes persistent sadness or anxiety, loss of interest, guilt, impaired concentration, and fatigue severe enough to interfere with everyday activities or care of the infant. Some affected mothers have difficulty forming an emotional bond with their baby or persistent doubts about their ability to provide care. Assessment must distinguish depressive symptoms from the physical demands of pregnancy, childbirth, and disrupted sleep. There is no single established cause: reproductive hormonal changes, genetic susceptibility, stressful circumstances, and the demands of caring for a newborn may contribute. Previous depression, bipolar disorder, or depression during an earlier pregnancy are relevant elements of the clinical history. (nimh.nih.gov)
Postpartum depression is distinct from the transient “baby blues”: mild mood changes, worry, unhappiness, and exhaustion commonly experienced during the first two weeks after delivery. Postpartum depression is more persistent or severe and can substantially impair functioning; severe symptoms are not defined as baby blues simply because they occur soon after childbirth. The US National Institute of Mental Health reports that most perinatal depressive episodes begin within four to eight weeks after birth, although depression can also begin during pregnancy or later in the postpartum months. Duration alone does not establish a diagnosis: symptom pattern, intensity, and impairment remain essential. (nimh.nih.gov)
The menopausal transition is another period in which depressive symptoms or episodes may emerge or recur. Irritability, anxiety, sadness, and loss of enjoyment may accompany this transition, but menopause does not inevitably produce depression. In a 2011 report, Joyce T. Bromberger and colleagues followed 221 women, aged 42–52 at entry, at the Pittsburgh site of the Study of Women’s Health Across the Nation. The odds of a major depressive episode were approximately two to four times higher during perimenopause or early postmenopause than during premenopause. This association remained after adjustment for previous major depression, stressful events, vasomotor symptoms, and annually measured reproductive hormone levels. Previous major depression was itself a strong predictor. These findings identify a period of increased vulnerability, but do not establish a simple hormone-deficiency explanation or imply that most women develop a depressive disorder. (nimh.nih.gov)
In later life, depression is not a normal consequence of aging, and sadness may be less prominent than emotional numbness, loss of interest, fatigue, sleep disturbance, or physical complaints. Recognition can be complicated by chronic pain, medical illness, medication effects, bereavement, and social isolation. Memory difficulties, slowed thinking, and impaired concentration also overlap with presentations of dementia and other cognitive disorders. The National Institute on Aging identifies depression, medication adverse effects, metabolic or endocrine disturbances, delirium, and neurodegenerative disease among possible causes of cognitive impairment. Depression-related cognitive symptoms may improve with treatment, but cognitive complaints cannot automatically be attributed to mood, nor do they by themselves establish dementia. Clinical assessment therefore considers mood, cognition, medical history, medication exposure, and changes in daily functioning together. (nia.nih.gov)
Psychological and Psychosocial Treatments
Cognitive behavioral therapy (CBT) treats depression by examining interactions among thoughts, emotions, and behavior. Therapist and patient identify recurrent interpretations—such as automatically treating a setback as evidence of personal inadequacy—and examine their accuracy and consequences. Structured sessions combine this work with problem-solving, monitoring of emotions and behavior, and practice between appointments. The objective is not simply to replace negative thoughts with positive ones, but to develop more accurate interpretations and coping skills that can be applied in everyday situations. Psychological treatment targets both depressive symptoms and difficulties in daily functioning; it may be delivered without medication or alongside it. (nimh.nih.gov)
Behavioral activation (BA) focuses more directly on the relationship between activity and mood. Treatment identifies patterns of withdrawal, inactivity, and avoidance, then uses planned behavioral changes to increase engagement with activities associated with improved mood. Activity monitoring and between-session assignments make this a structured intervention rather than general encouragement to “keep busy”; unlike cognitive restructuring, it does not directly target the content of thoughts. Its comparative effectiveness was examined in the 2016 UK COBRA randomized controlled trial, led by David Richards and colleagues. Among 440 adults with major depressive disorder, BA delivered by junior mental-health workers was non-inferior to CBT delivered by psychological therapists at 12 months. Mean PHQ-9 symptom scores were 8.4 in both groups in the modified intention-to-treat analysis, within the trial’s predefined non-inferiority margin of 1.9 points. This finding concerned those delivery arrangements and that adult clinical population, rather than establishing equivalence in every setting. (nice.org.uk)
Interpersonal psychotherapy (IPT) organizes treatment around current interpersonal difficulties associated with depressive symptoms: bereavement, disputes with significant others, changes in social roles, and loneliness or social isolation. Treatment connects changes in mood with interpersonal events and develops ways of handling the selected problem area. For example, work on a dispute can clarify each person’s expectations, examine communication difficulties, and rehearse alternative ways of expressing needs; work on a role transition can address losses associated with the previous role and adjustment to new relationships or responsibilities. IPT therefore emphasizes interpersonal responses rather than directly challenging depressive thoughts. Individual protocols are time-limited; NICE describes 8–16 sessions for less severe adult depression. The World Health Organization and Columbia University also published an eight-session group IPT manual in 2016 for supervised facilitators, including those without previous mental-health training. (iris.who.int)
Delivery formats include individual appointments, groups, telephone sessions, and guided psychological interventions using printed or digital materials. Guided self-help combines structured CBT, BA, problem-solving, or psychoeducation materials with practitioner support to encourage completion and review progress; NICE describes six to eight regular support sessions. It differs from entirely unguided material because human support is part of the intervention. A 2019 network meta-analysis of 155 trials involving 15,191 adults found that individual, group, telephone-administered, and guided self-help CBT reduced acute depressive symptoms more than waiting-list or usual-care controls. Participants included both people with diagnosed depressive disorders and people selected through elevated symptom scores. Broad comparisons found no statistically significant effectiveness differences among supported formats, although guided self-help had higher dropout than individual or group CBT. These results do not establish that every digital product has comparable effects. (nice.org.uk)
Evidence also distinguishes psychological treatment alone from treatment combined with antidepressants. Pim Cuijpers and colleagues’ 2020 network meta-analysis included 101 randomized trials and 11,910 adults, most with moderate-to-severe depression. At treatment completion, combined treatment produced a higher probability of response than psychotherapy alone (relative risk 1.27, 95% confidence interval 1.14–1.39) or medication alone (1.25, 1.14–1.37). Psychotherapy and medication alone did not differ significantly in response probability (0.99, 0.92–1.08). Response was principally defined as at least a 50% reduction on a depression symptom scale, not complete remission or restoration of occupational functioning. These pooled comparisons describe outcomes in the populations studied; they do not demonstrate a universal ordering of treatments for every age group, severity, or individual circumstance. (pubmed.ncbi.nlm.nih.gov)
Antidepressant Medication
Antidepressants comprise several drug classes with different pharmacological targets. Selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine and sertraline, inhibit serotonin transporters, increasing the availability of this neurotransmitter at synapses. Serotonin–norepinephrine reuptake inhibitors (SNRIs), including duloxetine and venlafaxine, inhibit reuptake of both serotonin and norepinephrine. Tricyclic antidepressants, such as amitriptyline and imipramine, also affect monoamine reuptake but act on additional receptors, contributing to their broader adverse-effect profiles. Monoamine oxidase inhibitors (MAOIs), including phenelzine and tranylcypromine, inhibit enzymes involved in monoamine breakdown. SSRIs and SNRIs are commonly prescribed because they generally produce fewer adverse effects than older classes, although tolerability differs between individual drugs and patients. (dailymed.nlm.nih.gov)
Other antidepressants do not fit these reuptake-inhibitor categories. Bupropion inhibits neuronal uptake of norepinephrine and dopamine rather than serotonin. Mirtazapine acts at presynaptic alpha-2 adrenergic receptors and several serotonin receptors rather than inhibiting monoamine reuptake; its precise antidepressant mechanism remains uncertain. These distinctions concern drug action, not proof that a particular neurotransmitter deficiency causes depression. Their adverse effects also differ: mirtazapine commonly causes sleepiness and weight gain, while bupropion carries a seizure risk. (dailymed.nlm.nih.gov)
Clinical improvement with conventional antidepressants generally develops over several weeks; the US National Institute of Mental Health describes a usual interval of 4–8 weeks, with sleep, appetite, energy, or concentration sometimes improving before mood. In a 2018 network meta-analysis led by Andrea Cipriani, 522 randomized controlled trials involving 116,477 adults with major depressive disorder compared 21 antidepressants with placebo or one another. All 21 were more effective than placebo for acute response, defined as at least a 50% reduction in symptom scores, with response odds ratios ranging from 1.37 to 2.13. These estimates describe group-level outcomes, not an individual probability of recovery; evidence certainty ranged from moderate to very low, and acute response did not establish long-term functional recovery. (nimh.nih.gov)
Adverse effects and interactions vary substantially. SSRIs and SNRIs can cause gastrointestinal symptoms, sweating, sleep disturbances, and sexual dysfunction; SNRIs can also increase blood pressure. Tricyclics can cause dry mouth, constipation, blurred vision, low blood pressure, and cardiac rhythm disturbances. Combining serotonergic medicines or supplements can produce serotonin syndrome, a potentially life-threatening reaction involving mental-status changes, autonomic disturbance, and neuromuscular abnormalities. MAOIs have important interactions with other medicines and tyramine-rich foods: phenelzine labeling identifies aged cheeses and other high-tyramine foods as potential triggers of hypertensive crises. (fda.gov)
Age-related warnings concern specific outcomes rather than a uniform increase in suicide risk. In the United States, antidepressant boxed warnings address increased suicidal thoughts and behaviors in children, adolescents, and young adults through age 24 in short-term trials. Pooled estimates reproduced in citalopram labeling show 14 additional affected patients per 1,000 treated below age 18 and five additional patients per 1,000 at ages 18–24 compared with placebo; these figures are not estimates of completed suicide. Separately, discontinuation symptoms can follow missed doses, dose reductions, or cessation. They include dizziness, nausea, insomnia, anxiety, and electric-shock sensations. NICE’s 2022 guidance distinguishes withdrawal from depressive relapse and notes that symptoms can sometimes be severe or last several weeks or months. (dailymed.nlm.nih.gov)
Ketamine and its S-enantiomer, esketamine, differ from conventional monoaminergic antidepressants by antagonizing the NMDA receptor, part of glutamatergic signaling; improvement can occur within hours. In the United States, the January 2025 esketamine nasal-spray label authorized treatment-resistant depression in adults either alone or with an oral antidepressant. Its separate indication for depressive symptoms accompanying acute suicidal ideation or behavior requires an oral antidepressant, and the label explicitly states that prevention of suicide or reduction of suicidal behavior has not been demonstrated. Administration occurs under professional supervision with at least two hours of observation because risks include sedation, dissociation, respiratory depression, and misuse. Racemic ketamine use for depression is distinct: a June 23, 2026 FDA warning reiterated that ketamine itself was not approved for any psychiatric disorder. (accessdata.fda.gov)
Brain Stimulation and Other Physical Interventions
Electroconvulsive therapy (ECT) delivers electrical pulses through scalp electrodes to induce a controlled seizure in the brain. Modern ECT uses short-acting general anesthesia and a muscle relaxant, with monitoring of seizure activity, breathing, and cardiovascular function. An acute course commonly comprises 6–12 sessions, although the number varies with response. Its clinical role includes severe depression with psychotic symptoms or inadequate response to other treatments. It may also be used when rapid improvement is necessary: England’s 2022 NICE guideline identifies life-threatening failure to eat or drink as an example, rather than requiring unsuccessful medication trials in every case. (nlm.nih.gov)
ECT’s cognitive adverse effects include immediate disorientation, difficulty learning new information around treatment, and loss of memories for events preceding treatment, including autobiographical experiences. Problems with new learning generally improve after the course, whereas some gaps in past memories can persist. Their extent varies with electrode placement, electrical stimulus parameters, and individual characteristics; improvement on a general cognitive test does not necessarily exclude autobiographical memory loss. Assessment therefore encompasses both depressive symptoms and cognitive effects. NICE’s 2022 recommendations also require discussion of anesthesia-related risks, medical comorbidities, and informed consent. Medication or less frequent continuation ECT may follow an effective acute course to reduce relapse risk. (nice.org.uk)
Repetitive transcranial magnetic stimulation (rTMS) uses a coil near the scalp to generate changing magnetic fields, which induce electrical currents in targeted areas of the cerebral cortex. Depression protocols commonly target the dorsolateral prefrontal cortex, influencing activity in networks involved in mood regulation. Unlike ECT, conventional rTMS does not intentionally induce a seizure and normally requires neither anesthesia nor muscle relaxation. Headache and scalp discomfort are common adverse effects; seizures are rare. Protocols differ in pulse frequency, coil design, and treatment duration. In the 2018 THREE-D randomized controlled trial, Daniel Blumberger and colleagues studied 414 adults with treatment-resistant depression at three Canadian centers. Three-minute intermittent theta-burst sessions were noninferior to conventional 37.5-minute, 10-Hz sessions for symptom improvement under the study’s specified conditions; this finding does not establish equivalence between all stimulation protocols. (nimh.nih.gov)
Vagus nerve stimulation (VNS) usually involves a surgically implanted chest pulse generator connected to the left vagus nerve in the neck. Intermittent pulses reach the brain indirectly through nerve pathways. On July 15, 2005, the United States FDA approved the VNS Therapy System as adjunctive long-term treatment for chronic or recurrent depression in adults aged at least 18 who were experiencing a major depressive episode and had not responded adequately to four or more adequate antidepressant treatments. This indication is distinct from experimental transcutaneous VNS, which stimulates through the skin. Deep brain stimulation instead places electrodes directly within selected brain regions and connects them to an implanted generator. Although used for certain neurological disorders, it remains experimental for depression; authorization for one condition does not establish efficacy or authorization for another. (accessdata.fda.gov)
Bright-light therapy has a different mechanism and clinical indication from electrical or magnetic stimulation. It is an established treatment for winter-pattern seasonal depression, exposing the eyes to visible light to influence biological timing associated with seasonal changes. NIMH describes clinical regimens using ultraviolet-filtered, 10,000-lux light boxes for approximately 30–45 minutes, usually in the morning. This is not ultraviolet tanning treatment. Eye disease and medications that increase light sensitivity can affect suitability and monitoring requirements. Evidence for treating an existing winter depressive episode should also be distinguished from evidence for preventing its onset: NIMH’s 2023 account notes that studies had not provided convincing evidence that starting light therapy before symptoms appear prevents seasonal episodes. Its winter-pattern indication does not imply an equivalent role in summer-pattern depression. (nimh.nih.gov)
Treatment Planning and Persistent Nonresponse
Clinical planning considers symptom severity and functional impairment, previous treatment benefits and adverse effects, coexisting physical and psychiatric conditions, and the person’s preferences. These factors influence the choice between psychological treatment, medication, or their combination, as well as the need for specialist involvement. NICE’s adult-depression guideline, published on 29 June 2022, treats further-line decisions as shared decisions rather than a fixed sequence of drugs. Its evidence review distinguishes nonresponse following psychological therapy, antidepressant medication, and combined treatment, because the evidence and available alternatives differ between these situations. (nice.org.uk)
Treatment-resistant depression is an operational description, not a uniform biological subtype. A common definition requires inadequate response to at least two antidepressant trials delivered at adequate doses for adequate durations. Definitions nevertheless differ over treatment duration, the required degree of improvement, and which previous treatments count. Bradley Gaynes and colleagues’ systematic review, published online in 2019, found no consensus definition; only 17% of intervention studies enrolled populations meeting the most frequently specified criteria. Consequently, studies using the same label may include substantially different patient groups, limiting comparisons of treatment effects. (pubmed.ncbi.nlm.nih.gov)
Persistent symptoms are not sufficient to establish resistance when treatment exposure has been inadequate. Reassessment examines whether medication was taken consistently, adverse effects prompted interruptions, psychotherapy sessions were missed, or continuing social adversity and coexisting illness impeded improvement. It also revisits the diagnosis when symptoms remain unresponsive. NICE identifies complete nonresponse after four weeks of antidepressant treatment at a recognized therapeutic dose, or four to six weeks of psychological or combined treatment, as a point for reviewing possible explanations—not as proof that all effective options have been exhausted. (nice.org.uk)
Further-line strategies include switching, which replaces an unsuccessful treatment; combination treatment, such as adding cognitive behavioural therapy to medication or using two antidepressants; and augmentation, which adds another agent, such as lithium or an antipsychotic, to an antidepressant. NICE’s evidence review found benefits from adding cognitive behavioural approaches after medication nonresponse. By contrast, it identified no direct evidence for its specific population of patients whose initial psychological therapy had failed, so recommendations for that situation also drew on other treatment evidence and committee experience. Complex medication combinations may require specialist consultation. (nice.org.uk)
The 2017 VAST-D randomized controlled trial, reported by Somaia Mohamed and colleagues, illustrates both potential benefit and additional harm. Among 1,522 US veterans with nonpsychotic major depression inadequately responsive to at least one antidepressant course, remission by 12 weeks occurred in 22.3% after switching to bupropion, 26.9% after adding bupropion, and 28.9% after adding aripiprazole. Aripiprazole augmentation significantly outperformed switching, but not bupropion augmentation; somnolence, akathisia, and weight gain were more frequent with aripiprazole. Because 85.2% of participants were men, the sample also limits generalization to other populations. (pmc.ncbi.nlm.nih.gov)
Additional monitoring is integral to augmentation rather than separate from its effectiveness assessment. Lithium requires serum-level monitoring and assessment of renal and thyroid function and calcium. Antipsychotic augmentation entails monitoring weight, glucose, lipids, and movement-related adverse effects. Medication combinations also introduce interaction risks: NICE identifies combinations of monoamine oxidase inhibitors with several other antidepressant classes as potentially dangerous. These burdens affect patient safety and whether an observed symptom benefit justifies continuing a particular regimen. (nice.org.uk)
Course, Recovery, and Recurrence
Response denotes substantial improvement rather than disappearance of depression; treatment trials commonly operationalize it as a reduction of at least 50% from the baseline symptom score. Remission denotes absent or minimal depressive symptoms, while partial remission describes improvement with clinically relevant symptoms remaining. Recovery is sustained remission sufficient to regard the episode as ended. Relapse conventionally means the return of a depressive episode before recovery, whereas recurrence means a new episode after recovery. Ellen Frank and colleagues proposed a consensus framework for these distinctions in 1991. Duration requirements nevertheless differ: the 2006 American College of Neuropsychopharmacology task force defined recovery after at least four months following remission without relapse, while NICE’s 2022 evidence review used “relapse” to encompass both relapse and recurrence. Consequently, apparently similar research outcomes may use different symptom thresholds and observation periods. (jamanetwork.com)
The longitudinal course can include a single episode followed by sustained recovery, distinct recurrent episodes separated by remission, or persistent symptoms with fluctuating severity. Improvement need not proceed directly from an episode to complete remission: subthreshold symptoms can remain between episodes or after treatment response. NICE identifies frequent or recent previous episodes, severe depression, incomplete response with residual symptoms, and continuing physical-health or social difficulties as factors associated with greater relapse risk. These factors describe groups rather than determine an individual outcome; estimates also depend on whether participants were recruited from community, primary-care, or specialist populations and on the length of follow-up. NICE’s 2022 review specifically noted insufficient evidence to establish relapse rates reliably across primary- and secondary-care settings. (pubmed.ncbi.nlm.nih.gov)
Continuation treatment extends treatment beyond acute improvement to consolidate remission and prevent relapse of the treated episode; maintenance treatment is longer-term treatment intended to prevent subsequent episodes. Their boundaries vary with the operational definition of recovery. In England, NICE’s 2022 guideline describes antidepressant treatment as typically continuing for at least six months after symptom remission, with regular review; longer-term prevention takes account of previous episodes, residual symptoms, adverse effects, and preferences. Its evidence review found benefits from continued antidepressants compared with placebo or no treatment over follow-up periods of up to two years. It also noted an interpretive limitation: discontinuation symptoms, especially after abrupt substitution with placebo, can raise depression scores and inflate apparent differences in relapse rates. (nature.com)
The 2021 ANTLER randomized controlled trial, led by Gemma Lewis and colleagues, studied 478 UK primary-care patients receiving long-term antidepressants who felt sufficiently well to consider stopping. Over 52 weeks, relapse occurred in 92 of 238 participants continuing medication (39%) and 135 of 240 assigned to taper and discontinue it (56%). The discontinuation group also experienced more withdrawal symptoms. These results concern a selected, previously treated population, not the natural course of all depressive episodes; continued medication reduced but did not eliminate relapse during the trial. (nejm.org)
Relapse-prevention cognitive behavioral therapy and mindfulness-based cognitive therapy address processes that may persist after acute symptoms improve. They include recognizing warning signs, identifying triggers, planning responses to setbacks, and developing alternatives to rumination or avoidance. Mindfulness-based cognitive therapy additionally cultivates awareness of thoughts and feelings without automatically treating them as facts. Willem Kuyken and colleagues’ 2016 individual-patient-data meta-analysis included nine randomized trials and 1,258 adults with recurrent depression in full or partial remission. Compared with non-MBCT conditions, MBCT was associated with a lower hazard of depressive relapse over approximately 60 weeks: hazard ratio 0.69, with a 95% confidence interval of 0.58–0.82. This evidence concerns prevention after improvement, rather than prevention of a first episode. (nice.org.uk)
Symptomatic recovery is distinct from restoration of social and occupational functioning and quality of life. In a 2019 six-year follow-up study of 914 participants from the Netherlands Study of Depression and Anxiety, symptom remission accompanied reduced disability, but some impairment remained, including difficulties with household activities, interpersonal functioning, and participation in society. A separate 2004 follow-up of people with severe recurrent depression found that those remitting with residual symptoms subsequently spent more time with depressive symptoms and had poorer social adjustment over eight to ten years. Thus, low symptom scores alone do not establish that work performance, relationships, or everyday functioning have returned to their previous levels. (pubmed.ncbi.nlm.nih.gov)
Prevention, Access to Care, and Social Context
Prevention of first onset aims to reduce the occurrence of an initial depressive disorder in people who have never experienced one; relapse prevention concerns people whose symptoms have improved after an episode. Preventive programmes may be universal, such as school-wide coping-skills education; selective, targeting groups with elevated risk; or indicated, targeting people with depressive symptoms below the diagnostic threshold. These distinctions matter because reduced symptom scores do not necessarily demonstrate prevention of a diagnosable episode, and studies enrolling participants with previous depression may measure prevention of recurrence as well as first onset. WHO identifies school-based coping programmes, interventions for parents of children with behavioural problems, and exercise programmes for older adults among evaluated community approaches, although their outcomes include symptom reduction as well as prevention. (pmc.ncbi.nlm.nih.gov)
A concrete example is Judy Garber and colleagues’ 2009 US randomized controlled trial involving 316 adolescents aged 13–17 whose parents had current or previous depressive disorders. Participants had elevated subdiagnostic symptoms, a history of depression, or both, but no current depressive disorder. The cognitive-behavioural programme comprised eight weekly 90-minute group sessions followed by six monthly continuation sessions. By the assessment following the continuation phase, depressive episodes had occurred in 21.4% of programme participants and 32.7% receiving usual care. The programme did not demonstrate an advantage among adolescents whose parent was currently depressed at baseline. Thus, this trial evaluated prevention in a defined high-risk population, including both first and subsequent episodes, rather than establishing effectiveness for all adolescents. (pubmed.ncbi.nlm.nih.gov)
Access depends on more than the existence of effective treatments. Stigma can discourage disclosure and help-seeking, while inadequate funding and workforce shortages limit available appointments. Charges for consultations or medicines, transport expenses, distance from services, and waiting times create additional barriers; entitlement to care does not guarantee timely, affordable delivery. Language differences and sensory or cognitive communication difficulties can obstruct assessment and participation in treatment. NICE’s adult-depression guideline describes service arrangements intended to address these obstacles, including appointments outside normal working hours, community-based locations, bilingual therapists or independent interpreters, and accessible communication methods such as sign-language interpretation. These are features of service design, not substitutes for clinical assessment. (who.int)
Integration into primary health care enables non-specialist workers to participate in depression care with specialist support. Collaborative care adds a designated case manager, planned follow-up, repeated outcome measurement, structured psychological treatment, medication review, and coordination between primary and specialist services. In Vikram Patel and colleagues’ 2010 MANAS trial, 24 primary-care facilities in Goa, India, were randomized to enhanced usual care or stepped collaborative care delivered by trained lay counsellors, physicians, and supervising specialists. Among participants with confirmed depressive or anxiety disorders, six-month recovery was 65.0% with collaborative care and 52.9% with enhanced usual care. Benefit was demonstrated in public facilities but not private facilities; these figures concern the combined group of common mental disorders, not depression alone. (who.int)
Social and cultural context also shapes communication and service delivery. NICE’s 2022 guideline notes that depressive distress may be expressed differently across cultures, making the person’s own account and cultural context relevant to recognition. Information about treatment must therefore accommodate language, cultural expectations, and communication needs. Family members can contribute observations and practical support, but their involvement does not replace the person’s participation in decisions. Informed consent, privacy, supported decision-making, and protection from discrimination are central to rights-based care. WHO’s 2021 community-service guidance describes person-centred services, peer support, supported living, and coordinated links with housing, education, employment, and social protection. Its framework treats community inclusion and human rights as service objectives alongside clinical recovery. (nice.org.uk)
Development of Modern Treatment and Research Methods
Modern antidepressant development accelerated in the 1950s through clinical observations rather than drugs designed from an established explanation of depression. In 1957, Roland Kuhn reported antidepressant effects of imipramine, which became a prototype tricyclic antidepressant; that year, Harry Loomer, John Saunders, and Nathan Kline published a clinical evaluation of iproniazid, an early monoamine oxidase inhibitor. These discoveries opened distinct approaches to modifying monoamine neurotransmission. Later development increasingly targeted particular transporters: fluoxetine, a selective serotonin reuptake inhibitor, received United States approval in 1987, and venlafaxine, a serotonin–norepinephrine reuptake inhibitor, in 1993. The success of such drugs established therapeutic targets, not proof that depression results from a single neurotransmitter deficiency. (pubmed.ncbi.nlm.nih.gov)
Structured psychological treatments made psychotherapy more amenable to comparative testing. Aaron Beck and colleagues evaluated cognitive therapy against antidepressant medication in a 1977 controlled trial, translating a psychological model into specified treatment procedures and measurable outcomes. A larger milestone was the National Institute of Mental Health Treatment of Depression Collaborative Research Program, reported by Irene Elkin and colleagues in 1989. It randomly assigned 250 outpatients to 16 weeks of cognitive behavioral therapy, interpersonal psychotherapy, imipramine with clinical management, or placebo with clinical management. All groups improved, but differences depended on the outcome examined and initial severity. The study illustrated why improvement within a treatment group does not, by itself, establish superiority over a comparator. (dradamvolungis.com)
Brain-stimulation research developed methods for evaluating both symptom relief and cognitive effects. Electroconvulsive therapy research has examined electrode placement, electrical pulse characteristics, and treatment scheduling, while repetitive transcranial magnetic stimulation introduced more spatially targeted stimulation without intentionally inducing a seizure. The first rTMS device cleared for depression by the United States Food and Drug Administration in 2008 was intended for patients who had not responded to at least one antidepressant during the current episode. Subsequent investigations have compared stimulation targets and accelerated schedules. NIMH’s March 2024 account distinguished authorized approaches from experimental magnetic seizure therapy and deep brain stimulation for depression; promising trial findings did not constitute equivalent regulatory authorization. (nimh.nih.gov)
Randomized controlled trials compare assigned interventions, whereas longitudinal studies repeatedly observe patients to investigate recovery, chronicity, and recurrence. Martin Keller and colleagues’ 1992 report followed 431 participants in the NIMH Collaborative Depression Study for five years: 50% recovered within six months, but 12% had not recovered by five years. Such observations characterize illness trajectories but do not isolate treatment effects as randomization can. Pragmatic studies address effectiveness in ordinary clinical settings. STAR*D used sequential treatment steps and measurement-based care in primary-care and psychiatric clinics. Its 2006 first-step analysis included 2,876 outpatients receiving citalopram; remission was 28% using the clinician-rated Hamilton scale and 33% using a self-report measure. These differing estimates demonstrate the importance of specifying outcome definitions. (pubmed.ncbi.nlm.nih.gov)
Heterogeneous presentations and incomplete response complicate interpretation of group averages. In a 2015 analysis, Eiko Fried and Randolph Nesse identified 1,030 symptom profiles among 3,703 STARD participants; the most frequent profile occurred in only 1.8%. The analysis reduced symptoms to present-or-absent categories and acknowledged possible effects of medical conditions and medications. It documented variation within a diagnostic category, rather than establishing distinct biological diseases. Together with STARD’s substantial first-step nonremission, these findings show why neither a shared diagnosis nor an average treatment effect guarantees an individual outcome. (pubmed.ncbi.nlm.nih.gov)
Ketamine research illustrates the transition from experimental findings to a clinically authorized intervention. A Yale team including John Krystal and Dennis Charney reported the first randomized trial of intravenous ketamine for depression in 2000; Carlos Zarate and colleagues extended the findings to treatment-resistant depression in 2006. Rapid symptom changes redirected attention toward glutamate signaling and the NMDA receptor, beyond conventional monoaminergic targets. This research contributed to United States approval of intranasal esketamine for treatment-resistant depression in 2019. However, identifying a useful drug target does not establish the disorder’s cause, and experimental ketamine-related compounds remain distinct from treatments with demonstrated clinical efficacy and authorization. (nimh.nih.gov)
References
- What Is Depression?psychiatry.org
- Depressive disorder (depression)who.int
- Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders (CDDR)who.int
- Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disordersiris.who.int
- About DSM-5-TRpsychiatry.org
- Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Editionpsychiatry.org
- Back to Basics: A Refresher on Treating Major Depressive Disorderpcl.psychiatry.uw.edu
- Persistent Depressive Disorderpsychiatry.org
- Depression — National Institute of Mental Healthnimh.nih.gov
- Depressive disorder (depression) — World Health Organizationwho.int
- DCP_Text.indd — World Health Organizationwho.int
- Mental Disorders in Primary Care: A WHO Educational Packageiris.who.int
- Zika Toolkit: Manual for Health Care Professionalsiris.who.int
- Recommendations | Depression in adults: treatment and management | Guidance | NICEnice.org.uk
- NG222 Full guidelinenice.org.uk
- Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Carepmc.ncbi.nlm.nih.gov
- Heterogeneity in major depression and its melancholic and atypical specifiers: a secondary analysis of STAR*Dpmc.ncbi.nlm.nih.gov
- Psychiatry.org - Seasonal Affective Disorder (SAD)psychiatry.org
- Mental disorderswho.int
- Principles of Epidemiology: Lesson 3, Section 2archive.cdc.gov
- Principles of Epidemiology in Public Health Practice, Third Editionarchive.cdc.gov
- Major Depressionnimh.nih.gov
- Cross-national epidemiology of DSM-IV major depressive episodepmc.ncbi.nlm.nih.gov
- Global Health Metrics: Depressive disorders—Level 3 causehealthdata.org
- Global Burden of Disease Study 2021 (GBD 2021) Disability Weightsghdx.healthdata.org
- The State of US Healthhealthdata.org
- A prospective investigation of major depressive disorder and comorbidity in abused and neglected children grown up.pubmed.ncbi.nlm.nih.gov
- Poverty, depression, and anxiety: Causal evidence and mechanismspubmed.ncbi.nlm.nih.gov
- Poverty, depression, and anxiety: Causal evidence and mechanismseconomics.mit.edu
- The association between loneliness and depressive symptoms among adults aged 50 years and older: a 12-year population-based cohort studypubmed.ncbi.nlm.nih.gov
- Stress generation, avoidance coping, and depressive symptoms: a 10-year modelpubmed.ncbi.nlm.nih.gov
- Stress Generation, Avoidance Coping, and Depressive Symptoms: A 10-Year Modelpmc.ncbi.nlm.nih.gov
- Trans-ancestry genome-wide study of depression identifies 697 associations implicating cell types and pharmacotherapiespmc.ncbi.nlm.nih.gov
- Looking at My Genes: What Can They Tell Me About My Mental Health?nimh.nih.gov
- Ketamine Reverses Neural Changes Underlying Depression-Related Behaviors in Micenimh.nih.gov
- Imaging Identifies Brain Regions and Chemicals Underlying Mood Disorders; May Lead to Better Treatmentsnimh.nih.gov
- Noninvasively Stimulating Deep Brain Areas to Treat Depression Symptomsnimh.nih.gov
- Suspect Gene Variants Boost PTSD Risk after Mass Shootingnimh.nih.gov
- Cracking the Ketamine Codenimh.nih.gov
- Depressionnimh.nih.gov
- Depression - National Institute of Mental Health (NIMH)nimh.nih.gov
- Recommendations | Bipolar disorder: assessment and management | Guidance | NICEnice.org.uk
- Depression Screening: MedlinePlus Medical Testmedlineplus.gov
- The Patient Health Questionnaire-2: validity of a two-item depression screenerpubmed.ncbi.nlm.nih.gov
- The PHQ-9: Validity of a Brief Depression Severity Measurepmc.ncbi.nlm.nih.gov
- A Rating Scale for Depressionpmc.ncbi.nlm.nih.gov
- Depression Assessment Instrumentsapa.org
- A New Depression Scale Designed to be Sensitive to Changecambridge.org
- Are Scores on English and French Versions of the PHQ-9 Comparable? An Assessment of Differential Item Functioningpmc.ncbi.nlm.nih.gov
- Facebook Live: Bipolar Disorder in Adultsnimh.nih.gov
- What Are Bipolar Disorders?psychiatry.org
- Clinical Descriptions and Diagnostic Requirements for ICD-11 Mental, Behavioural and Neurodevelopmental Disordersdrugsandalcohol.ie
- Prolonged Grief Disorderpsychiatry.org
- DSM-5-TR Update, September 2024psychiatry.org
- Chapter 4—Mental and Substance-Related Disorders: Diagnostic and Cross-Cutting Topicsncbi.nlm.nih.gov
- Understanding the Link Between Chronic Disease and Depressionnimh.nih.gov
- Suicidewho.int
- Adult Outpatient Brief Suicide Safety Assessment Guidenimh.nih.gov
- Recommendations: Self-harm: assessment, management and preventing recurrencenice.org.uk
- Teen Depression: More Than Just Moodiness — National Institute of Mental Healthnimh.nih.gov
- Perinatal Depression — National Institute of Mental Healthnimh.nih.gov
- Major depression during and after the menopausal transition: Study of Women's Health Across the Nation (SWAN)pubmed.ncbi.nlm.nih.gov
- Depression and Older Adults — National Institute on Agingnia.nih.gov
- Assessing Cognitive Impairment in Older Patients — National Institute on Agingnia.nih.gov
- Psychotherapies — National Institute of Mental Healthnimh.nih.gov
- Cost and Outcome of Behavioural Activation versus Cognitive Behavioural Therapy for Depression (COBRA): a randomised, controlled, non-inferiority trialpubmed.ncbi.nlm.nih.gov
- Group Interpersonal Therapy (IPT) for Depressionwho.int
- Group Interpersonal Therapy (IPT) for Depression — Manualiris.who.int
- A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depressionpubmed.ncbi.nlm.nih.gov
- Mental Health Medications — National Institute of Mental Healthnimh.nih.gov
- Depression Medicines — FDAfda.gov
- Citalopram tablets: prescribing information — DailyMeddailymed.nlm.nih.gov
- Duloxetine: prescribing information — DailyMeddailymed.nlm.nih.gov
- Nardil—phenelzine sulfate: prescribing information — DailyMeddailymed.nlm.nih.gov
- Bupropion hydrochloride: prescribing information — DailyMeddailymed.nlm.nih.gov
- Mirtazapine: prescribing information — DailyMeddailymed.nlm.nih.gov
- Spravato: prescribing information, January 2025 — FDAaccessdata.fda.gov
- Spravato—esketamine hydrochloride solution: prescribing information — DailyMeddailymed.nlm.nih.gov
- Ketamine Store: warning letter, June 23, 2026 — FDAfda.gov
- Brain Stimulation Therapies — National Institute of Mental Healthnimh.nih.gov
- Electroconvulsive therapy — MedlinePlus Medical Encyclopediamedlineplus.gov
- NG222 Full guideline — NICEnice.org.uk
- Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trialpubmed.ncbi.nlm.nih.gov
- Seasonal Affective Disorder — National Institute of Mental Healthnimh.nih.gov
- Seasonal Affective Disorder — NIMH publicationinfocenter.nimh.nih.gov
- NG222 Depression in adults: treatment and management: Evidence review D 07/05/2024nice.org.uk
- Defining treatment-resistant depression - PubMedpubmed.ncbi.nlm.nih.gov
- Rationale and impact | Depression in adults: treatment and management | Guidance | NICEnice.org.uk
- Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial - PMCpmc.ncbi.nlm.nih.gov
- Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial - PubMedpubmed.ncbi.nlm.nih.gov
- Report by the ACNP Task Force on Response and Remission in Major Depressive Disordernature.com
- Preventing relapse: Depression in adultspubmed.ncbi.nlm.nih.gov
- Preventing relapsencbi.nlm.nih.gov
- Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCTpubmed.ncbi.nlm.nih.gov
- Long-term disability in major depressive disorder: a 6-year follow-up studypubmed.ncbi.nlm.nih.gov
- Residual symptoms at remission from depression: impact on long-term outcomepubmed.ncbi.nlm.nih.gov
- Preventing the onset of major depressive disorder: A meta-analytic review of psychological interventionspmc.ncbi.nlm.nih.gov
- Prevention of depression in at-risk adolescents: a randomized controlled trialpubmed.ncbi.nlm.nih.gov
- Can people afford to pay for health care? Evidence on financial protection in 40 countries in Europeiris.who.int
- Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trialpubmed.ncbi.nlm.nih.gov
- Recommendations: Decision-making and mental capacitynice.org.uk
- Guidance on community mental health serviceswho.int
- Guidance on community mental health services: promoting person-centred and rights-based approachesiris.who.int
- Treatment of depressive states with an iminodibenzyl derivative (G 22355)pubmed.ncbi.nlm.nih.gov
- A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizerpubmed.ncbi.nlm.nih.gov
- The Discovery of Fluoxetine Hydrochloride (Prozac)nature.com
- Venlafaxine Extended Release Tablets: Prescribing Informationaccessdata.fda.gov
- Comparative efficacy of cognitive therapy and pharmacotherapy in the treatment of depressed outpatientsdradamvolungis.com
- National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatmentspubmed.ncbi.nlm.nih.gov
- Discover NIMH: Personalized and Targeted Brain Stimulation Therapiesnimh.nih.gov
- Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjectspubmed.ncbi.nlm.nih.gov
- Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practicepubmed.ncbi.nlm.nih.gov
- Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Studynimh.nih.gov
- Depression is not a consistent syndrome: An investigation of unique symptom patterns in the STAR*D studypubmed.ncbi.nlm.nih.gov